Valuation : Axogen, Inc.

Market Cap 2.6B 2.23B 2.1B 1.92B 3.58B 245B 3.6B 24.89B 9.62B 126B 9.75B 9.53B 400B P/E 2026 *
-115x
P/E 2027 * 483x
Enterprise Value 2.6B 2.23B 2.1B 1.92B 3.58B 245B 3.6B 24.89B 9.62B 126B 9.75B 9.53B 400B EV / Sales 2026 *
9.28x
EV / Sales 2027 * 7.84x
Free-Float
97.38%
Yield 2026 *
-
Yield 2027 * -
1 day-4.26%
1 week-6.61%
Current month-8.22%
1 month-3.39%
3 months+12.36%
6 months+59.10%
Current year+42.33%
1 week 46.26
Extreme 46.26
51.5
1 month 45.26
Extreme 45.255
52.91
Current year 27.54
Extreme 27.54
52.91
1 year 15.27
Extreme 15.2701
52.91
3 years 3.45
Extreme 3.45
52.91
5 years 3.45
Extreme 3.45
52.91
10 years 3.45
Extreme 3.45
56.85
Manager TitleAgeSince
Chief Executive Officer 66 09/08/2024
Director of Finance/CFO 42 12/05/2025
Chief Operating Officer 65 10/01/2025
Director TitleAgeSince
Director/Board Member 65 01/09/2016
Director/Board Member 58 15/05/2019
Chairman 70 09/08/2024
Date Insider Type Main position Quantity % Market Cap. Importance
9/2/26 A Sell

Director

-3,500 0.0065%
8/11/26 A Exercice

Director

40,059 0.0745%
8/10/26 A Exercice

Compliance Officer

202,500 0.3767%
Change 5-day change 1-year change 3-year change Capi.($)
-3.81%-6.61%+190.43%+734.86% 2.6B
-1.95%+0.50%+23.75%+16.44% 227B
-0.75%-0.17%+4.00%-16.82% 146B
-4.14%-4.58%-25.03%+18.15% 130B
-3.91%-3.72%-57.19%-14.07% 69.27B
-3.42%-4.08%+8.52%+17.51% 51.82B
+0.89%-0.94%-18.11%-12.85% 49.99B
-2.59%-1.98%+14.69%+28.92% 42.53B
-1.57%-0.58%+30.43%+53.09% 40.22B
-1.88%+3.33%+117.99%+35.15% 32.95B
Average -2.36%-1.46%+28.95%+86.04% 79.18B
Weighted average by Cap. -2.19%-1.43%+5.73%+11.80%

Financials

2026 *2027 *
Net sales 280M 240M 226M 206M 386M 26.44B 387M 2.68B 1.04B 13.54B 1.05B 1.03B 43.13B 331M 285M 268M 244M 457M 31.31B 459M 3.18B 1.23B 16.03B 1.24B 1.22B 51.07B
Net income -22.88M -19.68M -18.51M -16.9M -31.6M -2.16B -31.7M -219M -84.83M -1.11B -85.94M -84.06M -3.53B 4.76M 4.09M 3.85M 3.52M 6.58M 450M 6.6M 45.67M 17.65M 231M 17.88M 17.49M 735M
Net Debt - -
Logo Axogen, Inc.
Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel.
Employees
622
Date Price Change Volume
08/09/26 $46.59 -3.51% 121,023
04/09/26 $48.28 +2.51% 550,070
03/09/26 $47.10 -2.48% 951,253
02/09/26 $48.30 -3.17% 789,915
01/09/26 $49.88 -1.73% 596,566
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
48.28USD
Average target price
53.90USD
Spread / Average Target
+11.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AXGN Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!